Genomtec has conducted an analysis of its rapid genetic tests that confirmed their effectiveness in detecting all known variants of the SARS-CoV-2 virus including the recently discovered Omicron variant.
Genomtec has begun pilot production of analyzers for the first 15 Genomtec®ID devices. The analysers are being manufactured by the Genomtec team in the UK in close collaboration with the CDMO partner there. The start of production was made possible by the completion of the design and reliability testing of the analyzer components. The first 15 devices will be used in clinical comparative studies, the results of which will be used to register Genomtec®ID as an in-vitro diagnostic medical device under the IVD directive in the European Union in the first half of this year
– I am proud that our team has successfully completed the design and testing and in such a small space have managed to include all the necessary components to perform genetic diagnosis of infections. The analyzer is a small and lightweight device measuring 16.5 cm by 11.5 cm and 11 cm high. It fits in the palm of your hand and makes it easy to carry wherever and whenever you want. This small size is achieved by our patented technique of non-contact photonic heating and by using the latest technology in electronics and mechanics. – said Miron Tokarki, CEO and co-founder of Genomtec.
Genomtec®ID, is a technology platform that will provide patients with ultra-fast mobile genetic diagnostics performed using SNAAT® technology. Genomtec®ID allows the diagnostic process to be performed at the point of care, without the need for complex and time-consuming handling in the laboratory by qualified personnel.. The first panel of Genomtec®ID will test for 5-pathogens of respiratory diseases, including Influenza, RSV, SARS-CoV-2 and two atypical pneumoniae bacterial infections. The Company plans to register the Genomtec®ID platform in the middle of this year.